Treatment of Xanthelasma Palpebrarum With Intralesional Pingyangmycin.

Dermatol Surg

*Department of Plastic and Reconstructive Surgery, Changzheng Hospital, Second Military Medical University, Shanghai, China; †Department of Orthopedics, PLA 456 Hospital, Jinan, China.

Published: March 2016

Background: Xanthelasma palpebrarum (xanthelasma) is the most common type of cutaneous xanthoma, and many patients tend to seek medical treatments for cosmetic reasons. Many methods treating xanthelasma have been proposed, but none of these options can be regarded as a perfect solution.

Objective: To study and evaluate the intralesional injection treatment of xanthelasma with pingyangmycin, which has been widely used as a broad-spectrum antitumor antibiotic.

Materials And Methods: 21 lesions in 12 patients were treated by intralesional pingyangmycin. Photographs were taken before and after each treatment session. Patients were followed up for 7 to 36 months.

Results: All patients except one received satisfactory results after up to 2 sessions. Only 1 patient had a local recurrence 1 year after the treatment. No severe complications such as infection, atrophy, ulceration, or scar were noticed.

Conclusion: Intralesional pingyangmycin is a cheap, effective, and safe treatment for xanthelasma, which has been well accepted by patients.

Download full-text PDF

Source
http://dx.doi.org/10.1097/DSS.0000000000000660DOI Listing

Publication Analysis

Top Keywords

treatment xanthelasma
12
intralesional pingyangmycin
12
xanthelasma palpebrarum
8
treatment
5
xanthelasma
5
patients
5
intralesional
4
palpebrarum intralesional
4
pingyangmycin
4
pingyangmycin background
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!